▶ ADAMAX · SUBTOPIC · SAFETY PROFILE
ADAMAX Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of ADAMAX.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of ADAMAX. Severity, frequency, and attribution depend on the source publication.
- Limited human safety data
- Importantly: no erythropoietic activity at standard research doses (the engineering goal)
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for ADAMAX.
- Unstudied · theoretical interactions with EPO or anti-inflammatory medications
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for ADAMAX in the published record:
- Pregnancy/lactation (unstudied)
- Active malignancy (theoretical EPO-pathway concern)
FDA REGULATORY STATUS
Not FDA-approved. Research chemical.
WADA REGULATORY STATUS
EPO-class status under S2 may apply depending on specific analog. Buyers should verify with current WADA list.
SAFETY Q+A FROM LITERATURE
▶ Is Adamax FDA-approved?
No. Adamax is a research chemical. Cibinetide (the closely related ARA-290) has been investigated in small clinical trials for sarcoidosis-related small-fiber neuropathy; no FDA approval as of 2026.
▶ How does Adamax differ from EPO?
Native EPO activates both the homodimeric EPOR (driving erythropoiesis) and the IRR heterocomplex (driving tissue protection). Adamax-class peptides are engineered to selectively activate only the IRR, preserving the tissue-protective biology without the red-blood-cell-stimulating side effect.
▶ Side effects of Adamax?
Limited human safety data. The engineering goal is to avoid the erythropoietic side effects of native EPO; Adamax-class peptides should not raise hematocrit at standard research doses.
▶ Is Adamax banned in sports?
EPO and its analogs are prohibited at all times under WADA Section S2. Adamax's specific status depends on the exact analog; buyers should verify with the current WADA Prohibited List. Detection methods exist for the EPO peptide class.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Brines M, Patel NS, Villa P, et al.. ARA-290, a non-erythropoietic EPO analog, modulates inflammation and tissue protection. Mol Med 2014. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19